GALD.SW GALDERMA GROUP N | CH1335392721
Company Profile
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Latest News
Coinbase CEO Brian Armstrong Says Pivot From Crypto To AI Is 'Zero Sum, Scarcity Thinking'
Stocktwits • 07/27/2026
'Good energy' at Chelsea as Alonso kickstarts reign in Sydney
AFP • 07/27/2026
What To Expect From Acadia Healthcare’s (ACHC) Q2 Earnings
StockStory • 07/27/2026
Invitation to presentation of InstallatørGruppen's Q2 2026 Financial Report
GlobeNewswire • 07/27/2026
Rio Tinto and WA Government sign agreements with Yindjibarndi WaterCo for proposed sale of Dampier Seawater Desalination Plant
Business Wire • 07/27/2026
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.galderma.com |
| Audit Risk | 8 |
| Board Risk | 3 |
| Overall Risk | 5 |
| Market Cap | 40.49B |
| Trailing P/E | 58.47 |
| Forward P/E | 31.97 |
| Dividend Rate | 0.35 |
| Dividend Yield | 0.20% |
| Trailing Annual Div. Rate | 0.44 |
| Trailing Annual Div. Yield | 0.26% |
| Trailing EPS | 2.97 |
| Forward EPS | 5.43 |
| Book Value | 28.43 |
| Price-to-Book | 6.11 |
| Enterprise-to-Revenue | 8.15 |
| Enterprise-to-EBITDA | 37.66 |
| Ex-Dividend Date | 04/24/2026 |
| Dividend Date | 04/29/2025 |
| Earnings Date | |
| Earnings Call Date | 07/23/2026 |
| Revenue Average | 1.57B |
| Revenue Low | 1.57B |
| Revenue High | 1.57B |